Together, these data provide evidence that CRISPRδ can be harnessed to suppress pathogenic protein synthesis independent of template RNA degradation and raise the possibility of employing CRISPRδ as a therapeutic strategy for nucleotide-repeat diseases such as C9orf72 FTD/ALS. The gene discussed is C9orf72; the disease is frontotemporal dementia.